NEJM on Twitter: "Original Article: Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma https://t.co/0pcpqYVD59 https://t.co/Gheb94m7pa" / Twitter
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients | Journal for ImmunoTherapy of Cancer
![PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e9421b1f28d07120db03e4bd48eb87e8e203563c/14-Figure2-1.png "PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma | Semantic Scholar")
PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma | Semantic Scholar
Combinatorial benefit without synergy in recent clinical trials of immune checkpoint inhibitors | medRxiv
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Supplemental Materials for Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019 - European Journal of Cancer
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - Journal of Thoracic Oncology
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study | Journal for ImmunoTherapy of Cancer
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study - European Journal of Cancer
Combining Nivolumab & Ipilimumab Improved Overall Survival in Melanoma | Article | NursingCenter
![PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/23dbeed54cde655fb6a12697b02c9ff303515da7/11-Table2-1.png "PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar")
PDF] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Semantic Scholar
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology
![PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e9421b1f28d07120db03e4bd48eb87e8e203563c/13-Figure1-1.png "PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma | Semantic Scholar")
PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma | Semantic Scholar
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆ - ESMO Open
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain | NEJM
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | NEJM
Updated Data From Clinical Trials on Nivolumab/Ipilimumab in Advanced Melanoma - The ASCO Post
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study - European Journal of Cancer
